SHR6508 clinical trials
Also written SHR6508.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses SHR6508 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SHR6508
- 2
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses SHR6508 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical TrialCompletedPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06236295Written as SHR6508
- A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary HyperparathyroidismCompletedPhase 1Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06877247Written as [14C] SHR6508 Injection
- A Study of SHR6508 in Secondary HyperparathyroidismStatus unknownPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT05663411Written as SHR6508